ArticleDiabetology & metabolic syndrome2025
Brown adipose tissue: a potential therapeutic target for preventing cardiovascular disease in metabolic disorders.
Article in Diabetology & metabolic syndrome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Metabolic and biochemical profiling reveals phenotypic heterogeneity in Zucker diabetic fatty rats.Animal models and experimental medicine · 2026Article
- Vasoactive Effects of Chronic Treatment with ACE Inhibitor Zofenopril in Zucker Obese Diabetic Rats: The Role of Nitroso and Sul?de Signalization.Physiological research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundObesity and Type 2 diabetes (T2D) remain significant health challenges contributing to cardiovascular complications. This study aimed to investigate brown adipose tissue (BAT) and connexin43 (Cx43) in obese T2D rats and evaluate the effects of antioxidant Cemtirestat. Cx43 plays a crucial role in both BAT and heart function, yet its expression in T2D hearts remains underexplored. MATERIALS AND
methodsForty male Zucker diabetic fatty (ZDF) rats were divided into four groups: (1) lean nondiabetic (ZDF lean), (2) Cemtirestat-treated lean nondiabetic (ZDF lean + C), (3) obese diabetic (ZDF T2D), and (4) Cemtirestat-treated obese diabetic (ZDF T2D + C). After 6 months, biometric and biochemical parameters were measured and Cx43, selected protein kinases and batokines were analyzed in the BAT and left ventricle. Echocardiograms were recorded prior to study completion.
resultsObese T2D rats exhibited increased body weight, heart weight, visceral fat, BAT mass, glucose, insulin, cholesterol and triglycerides. Cx43 was decreased in BAT but increased in the left ventricles of T2D rats. Cemtirestat increased Cx43 in BAT of lean rats but not in the left ventricles of obese T2D rats. Protein kinase C epsilon was reduced in BAT, while protein kinase C delta was increased in both BAT and left ventricles of T2D rats and partially normalized by Cemtirestat. BAT whitening together with reduced mitochondrial uncoupling protein 1 and fibroblast growth factor 21 were observed in T2D rats. Echocardiography revealed diastolic dysfunction in T2D rats, which was attenuated by Cemtirestat.
conclusionThese findings support the role of BAT as a therapeutic target in metabolic disease and identify Cx43 as a molecular mediator linking adipose tissue dysfunction to cardiac impairment. Although low-dose Cemtirestat showed limited efficacy, it demonstrates potential for cardiometabolic intervention, justifying further investigation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.